Michael Amoroso appointed Senior Vice President, Americas Commercial, Oncology Business Group at Eisai Inc.

WOODCLIFF LAKE, N.J., Sept. 25, 2017 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., today announced the immediate appointment of Michael Amoroso as Senior Vice President, Americas Commercial, Oncology Business Group.

Michael Amoroso

Amoroso, who has over 20 years of experience in oncology and other therapeutic areas, will lead Eisai's Americas Oncology Commercial team in creating and driving commercial strategies for the company's approved products, pipeline assets and late-stage compounds approaching the commercialization stage. In addition to his functional responsibilities, Amoroso will serve as a member of the Eisai Inc. Americas Executive Committee. 

"Michael has been tremendously successful in launching oncology brands, developing and collaborating on disease awareness initiatives, repositioning global brand plans, crafting development plans with R&D and medical colleagues, and leading large cross-functional teams in working together to deliver high quality value to customers and patients," said Shaji Procida, President and Chief Operating Officer, Eisai Inc. "We are confident that his extensive experience and proven leadership will help drive the growth of Eisai's oncology business in the Americas."

Amoroso joins Eisai from Celgene, where he spent the last six years in a variety of marketing roles. Most recently, he served as Commercial Head, Global Markets for CAR-T programs, in which he developed the company's global organizational model to commercialize cell therapies involving specialized manufacturing and customer services for lymphoma and myeloma patients. He held prior roles in Global Marketing for the GI Oncology Franchise, and in US Oncology Marketing where he specialized in the breast, lung and pancreas cancer segments. Before Celgene, Amoroso served in a number of sales, sales leadership and marketing roles over his 10-plus year tenure at Sanofi Aventis, including being the brand lead for an oncology product with eight indications.    

Amoroso received his Master of Business Administration degree from the New York University's Stern School of Business. He earned his Bachelor of Arts degree from Rider University in Biological Sciences.

Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Co. Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Media Inquiries

Investor Inquiries

Patti Councill

Ivor Macleod

Eisai Inc.

Eisai Inc.





SOURCE Eisai Inc.

Type Press Release

Date Released September 25, 2017

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields